BAFFR targeting CAR-NK cell therapy - PeproMene Bio

Alternative Names: Allogeneic BAFFR CAR-NK cell therapy - PeproMene Bio; BAFFR Allo CAR-NK

Latest Information Update: 21 Jul 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PeproMene Bio
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Cancer

13 Jul 2023 BAFFR CAR-NK cell therapy - PeproMene Bio is available for licensing as of 13 Jul 2023. https://pepromenebio.com/baffr-car-nk-cells/ (PeproMene Bio website, July 2023)
13 Jul 2023 Early research in Cancer in USA (Parenteral) prior to July 2023 (PeproMene Bio pipeline, July 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com